GHR抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Raji, K562, skov3 and pc3 cell, Primary antibody: P10913(GHR Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

Growth hormone receptor (GHR) antibodies are tools used to study the structure, function, and signaling pathways of the growth hormone receptor, a transmembrane protein critical for mediating the effects of growth hormone (GH) in target tissues. GHR belongs to the cytokine receptor superfamily and activates intracellular signaling cascades, primarily the JAK2-STAT5 pathway, upon GH binding. This receptor plays a key role in growth regulation, metabolism, and cellular differentiation.

Antibodies targeting GHR have been developed for both research and clinical applications. In research, they help detect GHR expression in tissues, elucidate receptor-ligand interactions, and investigate dysregulation in conditions like Laron syndrome (a GH insensitivity disorder), cancer, or metabolic diseases. Monoclonal and polyclonal antibodies are commonly used in techniques such as Western blotting, immunohistochemistry, and flow cytometry.

Clinically, anti-GHR antibodies have therapeutic potential. For example, blocking antibodies may inhibit excessive GH signaling in acromegaly or certain cancers where GH pathways contribute to proliferation. Conversely, antibodies mimicking GH action are explored for treating growth disorders. However, challenges include ensuring specificity to avoid off-target effects and optimizing pharmacokinetics.

The development of GHR antibodies has advanced understanding of GH biology and opened avenues for targeted therapies, though their clinical translation requires careful evaluation of efficacy and safety profiles.